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Abstract
Background: Application of genetically modified bone marrow concentrates in articular cartilage lesions is a
promising approach to enhance cartilage repair by stimulating the chondrogenic differentiation processes in sites
of injury.
Method: In the present study, we examined the potential benefits of transferring the proliferative and
pro-chondrogenic basic fibroblast growth factor (FGF-2) to human bone marrow aspirates in vitro using the
clinically adapted recombinant adeno-associated virus (rAAV) vectors to monitor the biological and chondrogenic
responses over time to the treatment compared with control (lacZ) gene application.
Results: Effective, significant FGF-2 gene transfer and expression via rAAV was established in the aspirates relative
to the lacZ condition (from ~ 97 to 36 pg rhFGF-2/mg total proteins over an extended period of 21 days).
Administration of the candidate FGF-2 vector led to prolonged increases in cell proliferation, matrix synthesis, and
chondrogenesis but also to hypertrophic and terminal differentiation in the aspirates.
Conclusion: The present evaluation shows the advantages of rAAV-mediated FGF-2 gene transfer to conveniently
modify bone marrow concentrates as a future approach to directly treat articular cartilage lesions, provided that
expression of the growth factor is tightly regulated to prevent premature hypertrophy in vivo.
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Background
The adult articular cartilage has a limited ability for self-
repair (Buckwalter 1998) due to the absence of
vascularization in this particular joint tissue that may be a
potential source of chondrogenerative cells such as mes-
enchymal stem cells (MSCs) (Orth et al. 2014). While pro-
genitor cells can be made accessible within sites of injury
by procedures like marrow stimulation (Dewan et al.
2014; Madry et al. 2011), the outcomes of such techniques
do not match the expected native hyaline cartilage and in-
stead, a fibrocartilaginous repair tissue is formed in the
lesions with mostly type-I versus type-II collagen and pro-
teoglycans (Dewan et al. 2014). One-step administration
of bone marrow concentrates containing chondrogenically
competent MSCs (Anam and Davis 2013; Lennon et al.
2000) within cartilage defects rather than of isolated and/
or expanded MSCs raised important attention as a new,
convenient option to improve cartilage repair (Orth et al.
2014). Still, even when using such a straightforward
approach (Enea et al. 2013; Gigante et al. 2012; Kim et al.
2014; Orozco et al. 2013; Skowronski et al. 2013; Slynarski
et al. 2006; Wakitani et al. 2004), an original (structural
and functional) articular cartilage repair tissue could not
be regenerated in patients, demonstrating the necessity to
develop improved therapeutic strategies to manage cartil-
age injuries.
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The modification of bone marrow aspirates by gene
transfer technologies is a promising, new avenue of
translational research as a means to enhance the chon-
drogenic responses to injury by overexpressing target
candidates with potential reparative activities (Cucchiar-
ini et al. 2014; Frisch et al. 2015b). In this regard, a num-
ber of studies revealed the feasibility of applying
adenoviral vectors at very high doses (1010-1011) to pro-
mote the expression of reporter genes (E. coli β-
galactosidase, firefly luciferase, green fluorescent protein)
(Pascher et al. 2004) or therapeutic sequences including
the transforming growth factor beta (TGF-β) (Ivkovic et
al. 2010), bone morphogenetic protein 2 (BMP-2) (Sieker
et al. 2015), and Indian hedgehog (IHH) (Sieker et al.
2015) in marrow aspirates from rabbits and sheep but
only for relatively short periods of time (some days). In-
stead, we recently provided evidence that recombinant
adeno-associated virus (rAAV) vectors are adapted gene
vehicles to competently transduce human marrow con-
centrates over extended periods of time at very high effi-
ciencies (~90 % for at least 125 days) using much lower
vector doses (8 × 105) and without detrimental effect
(Rey-Rico et al. 2015) compared with the more immuno-
genic adenoviral vectors (Frisch et al. 2015b). We
showed for instance that effective rAAV-mediated over-
expression of the transcription factor SOX9 (Rey-Rico et
al. 2015) or of insulin-like growth factor I (IGF-I) (Frisch
et al. 2015a) was capable of activating the chondrogenic
processes in freshly prepared human marrow samples.
Here, we focused on delivering the basic fibroblast
growth factor (FGF-2) to human marrow aspirates in
light of the proliferative and pro-chondrogenic activities
of this agent in isolated human MSCs when applied as a
recombinant molecule (Solchaga et al. 2010; Solchaga et
al. 2005; Tsutsumi et al. 2001) or upon administration of
the current rAAV FGF-2 vector (Cucchiarini et al. 2011).
The present study reveals that delivery of rAAV allows
for an effective and durable production of FGF-2 in hu-
man marrow concentrates, allowing for enhanced levels
of cell proliferation, matrix synthesis, and chondrogenic
differentiation in such samples. Processes of hyper-
trophic and terminal differentiation were also activated,
suggesting that a critical regulation of transgene expres-
sion will be needed for FGF-2 using rAAV vectors prior
to translation of the approach in vivo. Nevertheless,
these findings reflect the value of rAAV gene transfer to
modify marrow concentrates for future procedures of
implantation in sites of cartilage damage.
Methods
Reagents
All reagents were from Sigma (Munich, Germany), unless
otherwise identified. Recombinant TGF-β (rTGF-β) was
purchased at Peprotech (Hamburg, Germany) and the
dimethylmethylene blue dye at Serva (Heidelberg,
Germany). The anti-FGF-2 (C-18) and anti-SOX9 (C-20)
antibodies were from Santa Cruz Biotechnology (Heidel-
berg, Germany), the anti-type-II collagen (II-II6B3) anti-
body from the NIH Hybridoma Bank (University of Iowa,
Ames, USA), the anti-type-I collagen (AF-5610) antibody
from Acris (Hiddenhausen, Germany), and the anti-type-
X collagen (COL-10) antibody from Sigma. Biotinylated
secondary antibodies and the ABC reagent were obtained
from Vector Laboratories (Alexis Deutschland GmbH,
Grünberg, Germany). The FGF-2 Quantikine ELISA
(DFB50) was from R&D Systems (Wiesbaden, Germany)
and the type-II, −I, and -X collagen ELISAs from
Antibodies-Online (Aachen, Germany).
Plasmids and rAAV vectors
All plasmids are based on the same parental AAV-2 gen-
omic clone, pSSV9 (Samulski et al. 1987; Samulski et al.
1989). rAAV-lacZ carries the lacZ gene encoding the E.
coli β-galactosidase (β-gal) and rAAV-hFGF-2 a human
basic fibroblast growth factor (hFGF-2) cDNA fragment
(480 bp), both under the control of the cytomegalovirus
immediate-early (CMV-IE) promoter (Cucchiarini et al.
2011; Frisch et al. 2015a; Rey-Rico et al. 2015). Conven-
tional (not self-complementary) rAAV vectors were
packaged using the 293 adenovirus-transformed embry-
onic kidney cell line. Helper functions were provided by
Adenovirus 5 in combination with rep and cap functions
of a pAd8 helper plasmid as previously described
(Cucchiarini et al. 2011; Frisch et al. 2015b). Purifica-
tion, dialysis, and titration of the vector preparations
via real-time PCR were performed, averaging 1010
transgene copies/ml with approximately 1/500 func-
tional recombinant viral particles (Cucchiarini et al.
2011; Frisch et al. 2015b; Rey-Rico et al. 2015).
rAAV-mediated gene transfer
Bone marrow was aspirated from the distal femurs of
patients undergoing total knee arthroplasty (~10 ml, n =
3). Aspirates were immediately aliquoted in a volume of
100 μl per well in 96-well plates and transduced with
40 μl vector (i.e. 8 × 105 functional recombinant viral
particles, MOI = 10 ± 3) (Frisch et al. 2015b; Rey-Rico et
al. 2015). Samples were incubated for up to 21 days with
chondrogenic medium (4.5 g/l DMEM high glucose, 100
U/ml penicillin, 100 μl/ml streptomycin, 6.25 μg/ml in-
sulin, 6.25 μg/ml transferrin, 6.25 μg/ml selenious acid,
5.35 μg/ml linoleic acid, 1.25 μg/ml BSA, 1 mM sodium
pyruvate, 37.5 μg/ml ascorbate 2-phosphate, 10−7 M
dexamethasone, and 10 ng/ml TGF-β3) with careful
weekly medium change as previously described (Cuc-
chiarini et al. 2011; Frisch et al. 2015b).
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Transgene expression
FGF-2 production was monitored by ELISA at the
denoted time points by absorbance measurements on a
GENios spectrophotometer/fluorometer (Tecan, Crail-
sheim, Germany) and by immunohistochemistry using a
specific FGF-2 antibody, a biotinylated secondary anti-
body, and diaminobenzidine as a chromogen (ABC
method) (Cucchiarini et al. 2011). A control condition
with omission of the primary antibody was included to
check for secondary immunoglobulins. All sections were
examined under light microscopy (Olympus BX45, Olym-
pus, Hamburg, Germany).
Biochemical analyses
The aspirates were resuspended in a total volume of
100 μl of fresh DMEM and digested with papain (final
concentration 75 μg/ml) at 60 °C (Frisch et al. 2015b).
The DNA contents were measured by fluorimetry using
Hoechst 22358 and the proteoglycan contents by bind-
ing to dimethylmethylene blue dye (Frisch et al. 2015b).
The type-II, −I, and -X collagen contents were deter-
mined by ELISA (Frisch et al. 2015a). Values were nor-
malized to total cellular proteins monitored via Pierce
Thermo Scientific Protein Assay (Fisher Scientific,
Schwerte, Germany). All measurements were performed
on a GENios spectrophotometer/fluorometer (Tecan).
Histological and immunohistochemical analyses
Aspirates were collected and fixed in 4 % formalin with
subsequent dehydration in graded alcohols, paraffin em-
bedding and sectioning at 3 μm. Hematoxylin eosin
(H&E) staining was performed to evaluate cellularity and
toluidine blue and alizarin red staining for the detection
of matrix proteoglycans and matrix mineralization, re-
spectively (Frisch et al. 2015a; Rey-Rico et al. 2015). The
expression of type-II, −I, and -X collagen and of SOX9
was evaluated by immunohistochemistry using specific
primary antibodies, biotinylated secondary antibodies
and the ABC method (Frisch et al. 2015b; Rey-Rico et al.
2015). Control conditions were included by omitting the
primary antibodies. All sections were examined under
light microscopy (Olympus BX45).
Histomorphometry
Cell proliferation was evaluated by counting the total
cells per standardized area on H&E-stained sections
(Frisch et al. 2015b). The intensities of H&E, toluidine
blue, and alizarin red staining and those of FGF-2, type-
II, −I, and -X collagen, and SOX9 immunostaining were
monitored at magnification ×20 by inverting the pictures
to grayscale mode, adapting background DAB signal for
comparable range, and measuring the mean gray value
per total area covered with cells (mm2) (Frisch et al.
2015b; Rey-Rico et al. 2015). The data were recorded at
three random standardized sites or with 10 serial histo-
logical and immunohistochemical sections for each par-
ameter, test and replicate condition using the SIS
analySIS program (Olympus) and Adobe Photoshop
(Adobe Systems, Unterschleissheim, Germany) and are
given as mean intensity of staining or immunostaining
in pixels per mm2 of total cell area (Frisch et al. 2015b;
Rey-Rico et al. 2015).
Real-time RT-PCR analyses
TRIzol reagent (Ambion® Life Technologies) and RNeasy
Protect Mini Kit (Qiagen, Hilden, Germany) were used
to extract total cellular RNA from all chondrogenically
differentiated aspirates on day 21 post-transduction. The
procedure included an on-column RNase-free DNase
treatment (Qiagen, Hilden, Germany) and extracted
RNA was eluted in 30 μl of RNase-free water followed
by reverse transcription using the 1st Strand cDNA Syn-
thesis kit for RT-PCR (AMV) (Roche Applied Science)
with aliquots of 8 μl RNA eluate. The resulting cDNA
products (≥2 μl per sample) were finally amplified by
real-time RT-PCR with Brilliant SYBR Green QPCR
Master Mix (Stratagene, Agilent Technologies, Wald-
bronn, Germany) on an Mx3000P QPCR operator sys-
tem (Stratagene) under the following conditions: (95 °C,
10 min), amplification by 55 cycles (denaturation at 95 °
C, 30 s; annealing at 55 °C, 1 min; extension at 72 °C,
30 s), denaturation (95 °C, 1 min), and final incubation
(55 °C, 30 s). Primers for selected gene profiles are listed
in Table 1 and applied at a final concentration of
150 nm. Controls consisting of water and non-reverse-
transcribed mRNA were included and confirmation of
the product specificities was done via melting curve ana-
lysis and agarose gel electrophoresis as previously de-
scribed (Frisch et al. 2015b). The MxPro QPCR Software
(Stratagene) was used for measurements of the threshold
cycle (Ct) value of each gene of interest and all values
were normalized to GAPDH expression using the 2-ΔΔCt
method (Frisch et al. 2015b).
Statistical analysis
Each condition was performed in duplicate in two inde-
pendent experiments for each patient. Data are
expressed as mean ± standard deviation (SD) of separate
experiments. The t-test and Mann–Whitney Rank Sum
Test were used where appropriate. Any P value of less
than 0.05 was considered statistically significant.
Results
Effective genetic modification of chondrogenically-
induced human bone marrow aspirates to overexpress
FGF-2 via rAAV gene transfer
Human bone marrow aspirates were first transduced
with the candidate rAAV-hFGF-2 vector versus control
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(rAAV-lacZ) condition and induced towards chondro-
genesis for up to 21 days to test the ability of rAAV to
mediate the overexpression of the candidate FGF-2. An
analysis of transgene expression revealed significantly
higher immunoreactivity to FGF-2 in the aspirates trans-
duced with rAAV-hFGF-2 compared with rAAV-lacZ
(1.7-fold difference, P = 0.009) (Fig. 1). These findings
were corroborated by measurements of the FGF-2 pro-
duction levels, with significantly higher values upon
FGF-2 gene transfer versus lacZ at any time point of the
analysis (up to 4.1-fold difference, P ≤ 0.003) (Table 2).
Effects of FGF-2 overexpression via rAAV upon the
proliferation and chondrogenic differentiation of
human bone marrow aspirates
Chondrogenically-induced aspirates were next trans-
duced with rAAV-hFGF-2 relative to rAAV-lacZ in
order to monitor the proliferative activities and differ-
entiation events in the samples following FGF-2 over-
expression. As we previously reported a lack of
deleterious effects of rAAV gene transfer upon the
potency of bone marrow aspirates (Rey-Rico et al.
2015), we did not test a condition lacking vector
treatment in this study.
Quantitative assessment of the intensities of H&E
staining and of the cell densities on histological sec-
tions from aspirates demonstrated significantly higher
values with rAAV-hFGF-2 compared with rAAV-lacZ
(up to 2.3-fold difference, P ≤ 0.027) (Fig. 2). These
results were supported by an estimation of the DNA
contents in the aspirates with significantly higher
values upon overexpression of FGF-2 (2.6-fold differ-
ence, P = 0.046) (Fig. 2).
To examine the influence of FGF-2 overexpression
on the chondrogenic events in the aspirates, the sam-
ples were processed to determine the levels of proteo-
glycan and type-II collagen deposition and the levels
Table 1 Primers used for real-time RT-PCR



















SOX9 SRY (sex determining region Y)-box 9, COL2A1 type-II collagen α1, ACAN
aggrecan, COL1A1 type-I collagen α1, COL10A1 type-X collagen α1, MMP13
matrix metallo-proteinase 13, ALP alkaline phosphatase, RUNX2 runt-related
transcription factor 2, GAPDH glyceraldehyde-3-phosphate dehydrogenase.
aChondrogenic markers; bOsteogenic markers; cHypertrophic and terminal dif-
ferentiation markers; dHousekeeping gene (control)
Fig. 1 Evaluation of FGF-2 overexpression in rAAV-transduced, chondrogenically-induced human bone marrow aspirates. The aspirates were transduced with
rAAV-lacZ or rAAV-hFGF-2 (40 μl each vector) and kept in chondrogenic medium for 21 days. The samples were processed to monitor FGF-2 production by
immunohistochemical analysis (magnification ×20; representative data) with corresponding histomorphometric assessments as described in the Methods.
*Statistically significant compared with rAAV-lacZ
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of SOX9 expression. Significantly increased intensities
were noted in the presence of rAAV-hFGF-2 relative
to rAAV-lacZ for toluidine blue staining (2.3-fold dif-
ference, P = 0.016), type-II collagen immunostaining
(1.2-fold difference, P = 0.002), and SOX9 immuno-
staining (1.3-fold difference, P = 0.037) (Fig. 3). These
findings were substantiated by an estimation of the
proteoglycan and type-II collagen contents (up to 2.3-
fold difference, P ≤ 0.022) (Fig. 3). Finally, real-time
RT-PCR analyses revealed 3.6-, 4.9-, and 1.9-fold in-
creases in the gene expression profiles of ACAN,
COL2A1, and SOX9, respectively (P ≤ 0.018) when
Table 2 Analysis of the levels of FGF-2 production in
rAAV-transduced, chondrogenically-induced human bone
marrow aspirates
Days post-transduction rAAV-lacZ rAAV-hFGF-2
7 23.6 (4.5) 96.7 (10.3)a
14 20.0 (1.5) 31.2 (2.4)a
21 22.2 (2.5) 36.2 (7.8)a
Values are expressed as means pg/mg total proteins/24 h (SD). aStatistically
significant compared with rAAV-lacZ
Fig. 2 Effects of FGF-2 overexpression upon the proliferative activities in rAAV-transduced, chondrogenically-induced human bone marrow aspi-
rates. The aspirates were transduced with rAAV-lacZ or rAAV-hFGF-2 as described in Fig. 1 and kept in chondrogenic medium for 21 days. The
samples were processed to evaluate the cell densities on H&E-stained histological sections (magnification ×20; representative data) with corre-
sponding histomorphometric assessments and to monitor the DNA contents as described in the Methods. *Statistically significant compared
with rAAV-lacZ
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Fig. 3 Effects of FGF-2 overexpression upon the production of cartilage-specific components in rAAV-transduced, chondrogenically-induced human bone
marrow aspirates. The aspirates were transduced with rAAV-lacZ or rAAV-hFGF-2 as described in the Figs. 1 and 2 and kept in chondrogenic medium for
21 days. The samples were processed to monitor the deposition of proteoglycans and of type-II collagen (toluidine blue staining and immunodetection,
respectively) and the expression of SOX9 (immunodetection) (all at magnification ×20; representative data) with corresponding histomorphometric assessments
and to estimate the proteoglycan and type-II collagen contents as described in the Methods. *Statistically significant compared with rAAV-lacZ
Frisch et al. Journal of Experimental Orthopaedics  (2016) 3:16 Page 6 of 10
applying rAAV-hFGF-2 compared with rAAV-lacZ
(please see Fig. 5).
Effects of FGF-2 overexpression via rAAV upon the
hypertrophic and terminal differentiation of human
bone marrow aspirates
Chondrogenically-induced aspirates treated with rAAV-
hFGF-2 versus rAAV-lacZ were finally processed to evi-
dence possible effects of transgenic FGF-2 expression
upon possible hypertrophic and terminal differentiation
events in the samples.
Significantly higher intensities were seen with rAAV-
hFGF-2 compared with rAAV-lacZ for alizarin red stain-
ing (1.2-fold difference, P = 0.017), type-I collagen im-
munostaining (1.3-fold difference, P = 0.006), and type-X
collagen immunostaining (1.2-fold difference, P = 0.040)
(Fig. 4). These findings were corroborated by an estima-
tion of the type-I and -X collagen contents (up to 2.3-
fold difference, P ≤ 0.028) (Fig. 3). Real-time RT-PCR
analyses also showed 3.1- and 1.7-fold increases in the
gene expression profiles of COL1A1 and COL10A1, re-
spectively (P ≤ 0.040) with rAAV-hFGF-2 relative to
rAAV-lacZ (Fig. 5). Such enhanced profiles with FGF-2
were associated with higher levels of MMP13, ALP, and
RUNX2 expression as markers of terminal differentiation
and osteogenesis (34.9-, 1.8-, and 62.5-fold, respectively,
P ≤ 0.023) (Fig. 5).
Discussion
Therapeutic gene transfer via clinically adapted rAAV
vectors is an attractive strategy to effectively and durably
enhance the chondrogenic processes in bone marrow
concentrates prior to re-implantation in sites of cartilage
injury (Cucchiarini et al. 2014; Frisch et al. 2015a). The
goal of this study was to demonstrate the possibility of
applying a functional rAAV construct carrying the se-
quence for the proliferative and pro-chondrogenic FGF-
2 (Solchaga et al. 2010; Solchaga et al. 2005; Tsutsumi et
al. 2001) to freshly prepared human marrow aspirates in
light of our previous findings in isolated human MSCs
(Cucchiarini et al. 2011) and of evidence showing the
potential of using such an approach to deliver reporter
genes and other candidate sequences (SOX9, IGF-I)
(Frisch et al. 2015b; Rey-Rico et al. 2015).
The results demonstrate that significant levels of FGF-
2 expression were achieved in the aspirates upon rAAV-
mediated gene transfer compared with control (lacZ)
transduction over the whole period of evaluation
(21 days), probably due to a good maintenance of this
vector class in these targets (Rey-Rico et al. 2015), in
agreement with our previous findings using the same
vector to target isolated human MSCs (Cucchiarini et al.
2011). The decrease in FGF-2 expression noted over
time may be due to a dilution of the transgene
sequences upon cell proliferation and expansion as the
rAAV vectors are mostly kept under (stable) episomal
forms in their targets. Interestingly, the amounts of fac-
tor produced in the aspirates over time following rAAV-
hFGF-2 application (~36 pg rhFGF-2/mg total proteins/
24 h after 21 days in chondrogenic medium) were lower
than those reported in MSCs (~137 pg/ml/24 h using
2 × 105 cells in chondrogenically-induced aggregate cul-
tures, i.e. ~ 360 pg rhFGF-2/mg total proteins/24 h and
a 10-fold difference) (Cucchiarini et al. 2011), reflecting
the presence of other cell subpopulations in the aspirates
(hematopoietic progenitor cells, hematopoietic cells, fi-
broblasts) that may not be a source of FGF-2 expression
after 21 days of continuous chondrogenic induction as
mostly the MSCs specifically and extensively commit to-
ward the chondrocyte phenotype in this environment
(Anam and Davis 2013; Frisch et al. 2015b; Lennon et al.
2000), being the major contributor of production over time.
Such sustained levels of FGF-2 generated from rAAV
gene delivery were capable of stimulating the prolifera-
tive, biosynthetic, and chondrogenic activities in the as-
pirates over time versus lacZ treatment, consistent with
the effects of FGF-2 when used in a recombinant form
(Solchaga et al. 2010; Solchaga et al. 2005; Tsutsumi et
al. 2001) or following application of the candidate
rAAV-hFGF-2 construct to isolated human MSCs (Cuc-
chiarini et al. 2011). The levels of proliferation reached
over time in the aspirates via FGF-2 gene transfer were
higher than those observed in isolated MSCs (~2.3 μg
versus ~ 1.1 ng DNA/mg total proteins after 21 days, re-
spectively, i.e. an ~ 2.1 × 103-fold difference) (Cucchiarini
et al. 2011), probably due to the presence of other mito-
genic factors in the samples secreted by all marrow pop-
ulations. Also, the levels of matrix biosynthesis in the
aspirates mediated over time by FGF-2 overexpression
were higher than those noted in isolated MSCs (~1087
versus ~ 170 pixels of standardized toluidine blue staining,
~ 66 versus ~ 0.9 ng proteoglycans/mg total proteins, and
~ 3.4 versus ~ 0.025 ng type-II collagen/mg total proteins
on day 21, respectively, i.e. an up to 136-fold difference)
(Cucchiarini et al. 2011), again possibly due to a more fa-
vorable biochemical and cellular environment for MSC
chondrogenesis in heterogeneous aspirates or to an up-
regulation of the levels of highly chondrogenic transcrip-
tion factor SOX9 (Bell et al. 1997; Lefebvre et al. 1997) by
FGF-2 in these samples versus isolated MSCs (Cucchiarini
et al. 2011), concordant with the reported stimulating ef-
fects of the growth factor on the activity of the sox9 gene
(Murakami et al. 2000).
Interestingly, the results also indicate that administra-
tion of the rAAV FGF-2 construct promoted the devel-
opment of hypertrophic and terminal differentiation
events in the aspirates in the particular conditions se-
lected, with enhanced levels of MMP13, ALP, and
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Fig. 4 Effects of FGF-2 overexpression upon the hypertrophic and terminal differentiation processes in rAAV-transduced, chondrogenically-
induced human bone marrow aspirates. The aspirates were transduced with rAAV-lacZ or rAAV-hFGF-2 as described in the Figs. 1, 2, and 3 and
kept in chondrogenic medium for 21 days. The samples were processed to monitor matrix mineralization (alizarin red staining) and the expression
of type-I and type-X collagen (immunodetection) (all at magnification ×20; representative data) with corresponding histomorphometric assessments
and to estimate the type-I and -X collagen contents as described in the Methods. *Statistically significant compared with rAAV-lacZ
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RUNX2 (markers of terminal and osteogenic differenti-
ation, transcription factor controlling the osteoblastic
expression of COL1, COL10, and MMP13) as previously
described with recombinant FGF-2 (Solchaga et al. 2010;
Solchaga et al. 2005; Tsutsumi et al. 2001) but in con-
trast with our findings when applying the current vector
to isolated MSCs (Cucchiarini et al. 2011). Such discrep-
ancy may be due to pro-hypertrophic activities induced
by other marrow subpopulations.
This study demonstrate the possibility of delivering a
candidate FGF-2 sequence to human bone marrow con-
centrates via rAAV vectors as a means to expand the pro-
cesses of chondrogenic differentiation in such samples in
vitro. It remains to be seen whether prolonged FGF-2 se-
cretion via rAAV may not lead to side (paracrine and auto-
crine) effects (activation of proliferation/differentiation of
undesirable cell populations), even though we did not ob-
serve such problems when applying directly the current
vector to focal experimental articular cartilage defects in
vivo (Cucchiarini et al. 2005). Work is now ongoing to
define the subpopulations participating in the chondro-
genic events in order to investigate cell heterogeneity
within the aspirates (Anam and Davis 2013; Jones et al.
2002; Lennon et al. 2000). We are also currently testing
the feasibility of translating the approach in vivo by
implanting genetically modified marrow aspirates within
experimental models of articular cartilage defects to
corroborate the observations in vitro (Cucchiarini et al.
2013; Ivkovic et al. 2010; Pascher et al. 2004; Sieker et
al. 2015). As application of rAAV FGF-2 led to prema-
ture hypertrophy and terminal differentiation in the as-
pirates, controlled expression of this factor as afforded
by using tissue-specific (type-II collagen, SOX9) or
regulatable promoters (tetracycline-sensitive) may allow
to restrain such possible, undesirable events in vivo. Al-
ternatively, combined gene transfer using extra, anti-
hypertrophic agents might be capable of circumventing
these effects in vivo like by co-applying the SOX9 tran-
scription factor (Cucchiarini et al. 2013; Rey-Rico et al.
2015). Overall, the present findings provide evidence on
the benefits of conveniently modifiying marrow aspi-
rates by rAAV gene transfer for future applications to
treat articular cartilage defects.
Conclusions
Genetic modification of bone marrow aspirates is a
promising avenue of translational research to treat cartil-
age defects in patients especially using clinically adapted
therapeutic rAAV vectors. The current study provides
evidence of the possibility to deliver the proliferative and
pro-chondrogenic FGF-2 to primary human marrow as-
pirates via rAAV for the durable commitment of the
samples toward chondrogenic differentiation. The occur-
rence of hypertrophic events in vitro suggests that con-
trolled expression of the growth factor will be a
prerequisite for future applications in vivo to effectively
treat cartilage lesions in the affected human population.
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21 days. The samples were processed to monitor the expression profiles of aggrecan (ACAN), type-II collagen (COL2A1), the transcription factor SOX9,
type-I collagen (COL1A1), type-X collagen (COL10A1), matrix metalloproteinase 13 (MMP13), alkaline phosphatase (ALP), and the transcription factor
RUNX2, with GAPDH serving as a housekeeping gene and internal control for normalization. Ct values were generated for each target gene and fold
inductions (relative to rAAV-lacZ-treated aspirates) were measured by using the 2-ΔΔCt method as described in the Methods. *Statistically significant
compared with rAAV-lacZ
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